12 assets in Gastrointestinal Stromal Tumor

Therapeutic assets addressing Gastrointestinal Stromal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Midazolam Gastrointestinal Stromal Tumor	Blueprint Medicines Corporation	P4	BBB (75)
Avapritinib Gastrointestinal Stromal Tumor	Blueprint Medicines Corporation	P3	BB (67)
Bezuclastinib Gastrointestinal Stromal Tumor	Cogent Biosciences, Inc.	P3	BB (66)
Ipilimumab Gastrointestinal Stromal Tumor	National Cancer Institute (NCI)	P2	B (59)
Belzutifan Gastrointestinal Stromal Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Nivolumab Gastrointestinal Stromal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Rogaratinib Gastrointestinal Stromal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-Oh (Ls301) Gastrointestinal Stromal Tumor	Washington University School of Medicine	P1/2	CCC (48)
Edotreotide Gastrointestinal Stromal Tumor	ITM Solucin GmbH	P1	CC (43)
nn3201 Gastrointestinal Stromal Tumor	Novelty Nobility, Inc.	P1	CC (43)
Olverembatinib Gastrointestinal Stromal Tumor	Ascentage Pharma Group Inc.	P1	CC (43)